Acute effects of lysergic acid diethylamide on circulating steroid levels in healthy subjects
In a double‑blind, placebo‑controlled crossover study in 16 healthy volunteers, a single 200 μg dose of LSD produced significant acute increases in circulating glucocorticoids (cortisol, cortisone, corticosterone and 11‑dehydrocorticosterone) and dehydroepiandrosterone. These steroid rises were temporally correlated with plasma LSD concentrations and peak psychedelic effects, with no evidence of acute pharmacological tolerance.
Authors
- Yasmin Schmid
- Patrick Dolder
- Matthias Liechti
Published
Abstract
Lysergic acid diethylamide (LSD) is a serotonin 5‐hydroxytryptamine‐2A (5‐HT2A) receptor agonist that is used recreationally worldwide. Interest in LSD research in humans waned after the 1970s, although the use of LSD in psychiatric research and practice has recently gained increasing attention. LSD produces pronounced acute psychedelic effects, although its influence on plasma steroid levels over time has not yet been characterised in humans. The effects of LSD (200 μg) or placebo on plasma steroid levels were investigated in 16 healthy subjects using a randomised, double‐blind, placebo‐controlled, cross‐over study design. Plasma concentration–time profiles were determined for 15 steroids using liquid‐chromatography tandem mass‐spectrometry. LSD increased plasma concentrations of the glucocorticoids cortisol, cortisone, corticosterone and 11‐dehydrocorticosterone compared to placebo. The mean maximum concentration of LSD was reached at 1.7 h. Mean peak psychedelic effects were reached at 2.4 h, with significant alterations in mental state from 0.5 h to > 10 h. Mean maximal concentrations of cortisol and corticosterone were reached at 2.5 h and 1.9 h, and significant elevations were observed 1.5–6 h and 1–3 h after drug administration, respectively. LSD also significantly increased plasma concentrations of the androgen dehydroepiandrosterone but not other androgens, progestogens or mineralocorticoids compared to placebo. A close relationship was found between plasma LSD concentrations and changes in plasma cortisol and corticosterone and the psychotropic response to LSD, and no clockwise hysteresis was observed. In conclusion, LSD produces significant acute effects on circulating steroids, especially glucocorticoids. LSD‐induced changes in circulating glucocorticoids were associated with plasma LSD concentrations over time and showed no acute pharmacological tolerance.
Research Summary of 'Acute effects of lysergic acid diethylamide on circulating steroid levels in healthy subjects'
Introduction
Lysergic acid diethylamide (LSD) is a prototypic serotonergic hallucinogen that acts primarily at serotonin 5-HT1 and 5-HT2 receptors and has a pharmacology that also includes dopaminergic and adrenergic receptor interactions. Earlier research showed that many psychoactive drugs activate the hypothalamic–pituitary–adrenal (HPA) axis and raise glucocorticoid levels, but data on LSD's effects on circulating steroid hormones in humans have been limited and fragmentary. Animal studies and early human urine studies suggested HPA activation after LSD, and a prior human report by the group found an increase in plasma cortisol at 180 min, but comprehensive time courses and a broader steroid panel had not been examined over the full duration of LSD's effects. Strajhar and colleagues set out to characterise the acute effects of a single oral dose of LSD on a wide panel of plasma steroids over 24 h in healthy volunteers and to compare steroid time-courses with LSD plasma concentrations and psychotropic effects. The study aimed to determine which steroid classes (glucocorticoids, mineralocorticoids, androgens, progestogens) are altered by LSD, the timing of those changes relative to subjective effects and LSD exposure, and whether any concentration–effect hysteresis or acute tolerance is evident.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topic
- Authors
- APA Citation
Strajhar, P., Schmid, Y., Liakoni, E., Dolder, P. C., Rentsch, K. M., Kratschmar, D. V., Odermatt, A., & Liechti, M. E. (2016). Acute effects of lysergic acid diethylamide on circulating steroid levels in healthy subjects. Journal of Neuroendocrinology, 28(3). https://doi.org/10.1111/jne.12374
References (9)
Papers cited by this study that are also in Blossom
Passie, T., Halpern, J. H., Stichtenoth, D. O. et al. · CNS Neuroscience and Therapeutics (2008)
Schmid, Y., Enzler, F., Gasser, P. et al. · Biological Psychiatry (2015)
Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)
Grossman, L., Utterback, E., Stewart, A. et al. · Behavioural Brain Research (2010)
´dric, C., Hysek, M., Schmid, Y. et al. · Social Cognitive and Affective Neuroscience (2013)
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
Dolder, P. C., Schmid, Y., Haschke, M. et al. · International Journal of Neuropsychopharmacology (2015)
Rickli, A., Luethi, D., Reinisch, J. et al. · Neuropharmacology (2015)
Hasler, F., Grimberg, U., Benz, M. A. et al. · Psychopharmacology (2004)
Cited By (22)
Papers in Blossom that reference this study
Erne, L., Vogt, S. B., Müller, L. et al. · Neuropsychopharmacology (2024)
Caspani, G., Ruffell, S. G. D., Tsang, WF. et al. · Pharmacological Research (2024)
Rudin, D., Areesanan, A., Liechti, M. E. et al. · Frontiers in Psychiatry (2023)
Dursun, S. M., Kelly, J. R., Gillan, C. M. et al. · Frontiers in Psychiatry (2021)
Strumila, R., Guillaume, S. · Pharmaceuticals (2021)
Holze, F., Avedisian, I., Varghese, N. et al. · Frontiers in Pharmacology (2021)
Bement, W., Banks, M. I., Zahid, Z. et al. · Molecular Biology of the Cell (2021)
Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)
DiVito, A. J., Leger, R. F. · Molecular Biology Reports (2020)
Brouwer, A., Carhart-Harris, R. L. · Journal of Psychopharmacology (2020)
Show all 22 papersShow fewer
Kelly, J. R., Crockett, M. T., Alexander, L. et al. · Irish Journal of Psychological Medicine (2020)
Schindler, E. A. D., Wallace, R. M., Sloshower, J. A. et al. · Frontiers in Pharmacology (2018)
Nichols, D. E. · ACS Chemical Neuroscience (2018)
Nichols, D. E., Grob, C. S. · Forensic Science International (2018)
Adams, T. · Biorxiv (2018)
Schmid, Y., Liechti, M. E. · Psychopharmacology (2017)
Liechti, M. E., Dolder, P. C., Grünblatt, E. et al. · Frontiers in Pharmacology (2017)
Dolder, P. C., Müller, F., Schmid, Y. et al. · Psychopharmacology (2017)
Liechti, M. E. · Neuropsychopharmacology (2017)
Dolder, P. C., Schmid, Y., Steuer, A. E. et al. · Clinical Pharmacokinetics (2017)
Liechti, M. E., Dolder, P. C., Schmid, Y. · Psychopharmacology (2016)
Dolder, P. C., Schmid, Y., Müller, F. et al. · Neuropsychopharmacology (2016)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.